97
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women

, , &
Pages 525-535 | Published online: 29 Aug 2017

Figures & data

Table 1 Unit costs included in the analysis

Table 2 Demographics and health care history of women with diagnosis of uterine fibroids: comparison between surgical and nonsurgical patients

Figure 1 Number of patients, included in the main study, divided according to the following criteria: health districts in nonsurgical patients (A), age groups in nonsurgical patients (B), type of surgery in surgical patients (C), and age groups in surgical patients (D).

Abbreviation: GnRH, gonadotropin-releasing hormone.
Figure 1 Number of patients, included in the main study, divided according to the following criteria: health districts in nonsurgical patients (A), age groups in nonsurgical patients (B), type of surgery in surgical patients (C), and age groups in surgical patients (D).

Table 3 Demographics and health care history of women with diagnosis of uterine fibroids treated with GnRH analogs or ulipristal acetate

Figure 2 Number of prescribed and reimbursed medication packages per patient. Ulipristal (A) and GnRH analogs (B).

Abbreviation: GnRH, gonadotropin-releasing hormone.
Figure 2 Number of prescribed and reimbursed medication packages per patient. Ulipristal (A) and GnRH analogs (B).

Figure 3 Distribution of total direct costs per patients in the main study: overall (A) and divided by surgical and nonsurgical patient groups (B).

Figure 3 Distribution of total direct costs per patients in the main study: overall (A) and divided by surgical and nonsurgical patient groups (B).

Figure 4 Distribution of total direct costs per patients in the ancillary study: overall (A) and divided by GnRH and ulipristal acetate patient groups (B).

Abbreviation: GnRH, gonadotropin-releasing hormone.
Figure 4 Distribution of total direct costs per patients in the ancillary study: overall (A) and divided by GnRH and ulipristal acetate patient groups (B).